153 related articles for article (PubMed ID: 36815391)
1. A severe case of primary erythromelalgia presenting as small fiber neuropathy with a novel SCN9A mutation.
Watabe D; Tominaga M; Toyama S; Takamori K; Nakano H; Amano H
J Dermatol; 2023 Jul; 50(7):938-941. PubMed ID: 36815391
[TBL] [Abstract][Full Text] [Related]
2. A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7.
Wu B; Zhang Y; Tang H; Yang M; Long H; Shi G; Tang J; Shi X
Curr Mol Med; 2017; 17(6):450-457. PubMed ID: 28990532
[TBL] [Abstract][Full Text] [Related]
3. Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations.
Emery EC; Habib AM; Cox JJ; Nicholas AK; Gribble FM; Woods CG; Reimann F
J Neurosci; 2015 May; 35(20):7674-81. PubMed ID: 25995458
[TBL] [Abstract][Full Text] [Related]
4. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia.
Klein CJ; Wu Y; Kilfoyle DH; Sandroni P; Davis MD; Gavrilova RH; Low PA; Dyck PJ
J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):386-91. PubMed ID: 23129781
[TBL] [Abstract][Full Text] [Related]
5. Bilateral congenital corneal anesthesia in a patient with SCN9A mutation, confirmed primary erythromelalgia, and paroxysmal extreme pain disorder.
Kim DT; Rossignol E; Najem K; Ospina LH
J AAPOS; 2015 Oct; 19(5):478-9. PubMed ID: 26486037
[TBL] [Abstract][Full Text] [Related]
6. Erythromelalgia caused by the missense mutation p.Arg220Pro in an alternatively spliced exon of SCN9A (NaV1.7).
Deuis JR; Kumble S; Keramidas A; Ragnarsson L; Simons C; Pais L; White SM; Vetter I
Hum Mol Genet; 2024 Jan; 33(2):103-109. PubMed ID: 37721535
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia.
Cregg R; Laguda B; Werdehausen R; Cox JJ; Linley JE; Ramirez JD; Bodi I; Markiewicz M; Howell KJ; Chen YC; Agnew K; Houlden H; Lunn MP; Bennett DL; Wood JN; Kinali M
Neuromolecular Med; 2013 Jun; 15(2):265-78. PubMed ID: 23292638
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series.
Arthur L; Keen K; Verriotis M; Peters J; Kelly A; Howard RF; Dib-Hajj SD; Waxman SG; Walker SM
J Pediatr; 2019 Mar; 206():217-224.e9. PubMed ID: 30416015
[TBL] [Abstract][Full Text] [Related]
9. Mutation in Na
Haehner A; Hummel T; Heinritz W; Krueger S; Meinhardt M; Whitcroft KL; Sabatowski R; Gossrau G
Eur J Pain; 2018 Nov; 22(10):1767-1773. PubMed ID: 29934995
[TBL] [Abstract][Full Text] [Related]
10. An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder.
Meijer IA; Vanasse M; Nizard S; Robitaille Y; Rossignol E
Muscle Nerve; 2014 Jan; 49(1):134-8. PubMed ID: 23893323
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-function mutation of a voltage-gated sodium channel Na
Tanaka BS; Nguyen PT; Zhou EY; Yang Y; Yarov-Yarovoy V; Dib-Hajj SD; Waxman SG
J Biol Chem; 2017 Jun; 292(22):9262-9272. PubMed ID: 28381558
[TBL] [Abstract][Full Text] [Related]
12. Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile.
McDonnell A; Schulman B; Ali Z; Dib-Hajj SD; Brock F; Cobain S; Mainka T; Vollert J; Tarabar S; Waxman SG
Brain; 2016 Apr; 139(Pt 4):1052-65. PubMed ID: 26920677
[TBL] [Abstract][Full Text] [Related]
13. Primary erythromelalgia: a review.
Tang Z; Chen Z; Tang B; Jiang H
Orphanet J Rare Dis; 2015 Sep; 10():127. PubMed ID: 26419464
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-the LENSS study.
de Greef BT; Merkies IS; Geerts M; Faber CG; Hoeijmakers JG
Trials; 2016 Jun; 17(1):306. PubMed ID: 27363506
[TBL] [Abstract][Full Text] [Related]
15. [Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment].
Doppler K; Sommer C
Nervenarzt; 2013 Dec; 84(12):1428-35. PubMed ID: 24202110
[TBL] [Abstract][Full Text] [Related]
16. Life-threatening hypothermia in a child with primary erythromelalgia.
Matarneh B; Witman P
Pediatr Dermatol; 2022 Jan; 39(1):135-136. PubMed ID: 34888934
[TBL] [Abstract][Full Text] [Related]
17. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
Natkunarajah J; Atherton D; Elmslie F; Mansour S; Mortimer P
Clin Exp Dermatol; 2009 Dec; 34(8):e640-2. PubMed ID: 19549232
[TBL] [Abstract][Full Text] [Related]
18. A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers.
Wu MT; Huang PY; Yen CT; Chen CC; Lee MJ
PLoS One; 2013; 8(1):e55212. PubMed ID: 23383113
[TBL] [Abstract][Full Text] [Related]
19. Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation.
Eberhardt M; Nakajima J; Klinger AB; Neacsu C; Hühne K; O'Reilly AO; Kist AM; Lampe AK; Fischer K; Gibson J; Nau C; Winterpacht A; Lampert A
J Biol Chem; 2014 Jan; 289(4):1971-80. PubMed ID: 24311784
[TBL] [Abstract][Full Text] [Related]
20. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models.
Xue Y; Chidiac C; Herault Y; Gaveriaux-Ruff C
Neurosci Lett; 2021 May; 753():135844. PubMed ID: 33775738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
